Caricamento...
Bevacizumab as a steroid‐sparing agent during immunotherapy for melanoma brain metastases: A case series
BACKGROUND: Brain metastases are common in advanced melanoma and often necessitate corticosteroids such as dexamethasone to control symptoms and reduce peritumoral edema. Immunotherapy improves survival in metastatic melanoma, but concomitant treatment with corticosteroids may reduce efficacy. Here,...
Salvato in:
| Pubblicato in: | Health Sci Rep |
|---|---|
| Autori principali: | , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
John Wiley and Sons Inc.
2019
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6427059/ https://ncbi.nlm.nih.gov/pubmed/30937392 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/hsr2.115 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|